For decades, the Randomized Controlled Trial (RCT) has been the undisputed gold standard for clinical evidence. Its rigorous, controlled, and often double-blinded design is excellent at answering a critical question: “Does this treatment work under ideal, laboratory-like conditions?” However, the very strengths that make RCTs so scientifically pure also create their limitations. They are incredibly expensive, can take years to complete, and often exclude the very patients who will use the treatment in the real world—the elderly, those with multiple chronic conditions, and those from diverse socioeconomic backgrounds. Their strict protocols don’t reflect the chaos of normal life.

This has led to a crucial question: How does a treatment work in the messy, complicated reality of everyday life? To answer that, the healthcare industry is turning to Real-World Evidence (RWE).

RWE is the clinical evidence derived from the analysis of Real-World Data (RWD)—data collected from sources outside of traditional clinical trials. This includes electronic health records, insurance claims, pharmacy data, and, increasingly, data from patient support programs and wearable devices. RWE gives us a clear picture of how treatments work across broad, unselected patient populations over long periods.

It’s important to see RWE not as a replacement for RCTs, but as a powerful and essential partner. The future of clinical validation is not an “either/or” debate, but a “both/and” strategy where each methodology complements the other. RWE can be used to:

• Design better, more efficient trials by analyzing existing RWD to identify the right patient populations, create more realistic inclusion/exclusion criteria, and establish more relevant endpoints. This can save millions of dollars and years of development time.
• Provide long-term safety and effectiveness data for years after a trial has ended. RCTs are often too short to capture rare or delayed adverse events, a gap that RWE can fill perfectly through ongoing post-market surveillance.
• Study rare diseases where conducting a large RCT with thousands of patients is simply not feasible. RWE allows researchers to pool data from disparate sources to generate meaningful insights and offer hope to these patient communities.
• Support regulatory and reimbursement decisions. Health Canada and the FDA are increasingly accepting RWE submissions to support approvals, especially for expanding the approved uses of an existing drug (label expansion). Furthermore, RWE is critical for demonstrating ongoing value to payers.

For many digital health interventions, such as a wellness app or a digital therapeutic, a traditional blinded trial is often conceptually impossible. For these innovations, RWE is becoming the primary method of demonstrating value and effectiveness to clinicians, payers, and patients. By intelligently integrating RWE into the evidence-generation process, we can get safer, more effective, and more equitable treatments to patients faster and more affordably. It represents a more pragmatic, efficient, and holistic approach to understanding what truly works in healthcare.